Company Description
Biomerica, Inc., a biomedical technology company, develops, patents, manufactures, and markets diagnostic and therapeutic products for the detection and/or treatment of medical conditions and diseases worldwide.
The company's diagnostic test kits are used to analyze blood, urine, nasal or fecal specimens from patients in the diagnosis of various diseases, food intolerances, and other medical complications; or to measure bacteria, hormones, antibodies, antigens, or other substances which may exist in the human body, stools, or blood in extremely small concentrations.
It primarily sells its products for gastrointestinal diseases, food intolerances, and various esoteric tests at the physicians' offices and over-the-counter drugstores, and hospital/clinical laboratories.
The company is also developing InFoods IBS, that uses a simple blood sample to identify patient-specific foods which may alleviate irritable bowel syndrome symptoms; and H.
Pylori diagnostic test that indicates if a patient is infected with the H. Pylori bacteria.
In addition, it develops products to indicate if a person has been infected by COVID-19. Biomerica, Inc. was incorporated in 1971 and is headquartered in Irvine, California.
| Country | United States |
| Founded | 1971 |
| Industry | Medical Devices |
| Sector | Healthcare |
| Employees | 62 |
| CEO | Zackary S. Irani |
Contact Details
Address: 17571 Von Karman Avenue Irvine, California 92614 United States | |
| Phone | (949) 379-2875 |
| Website | biomerica.com |
Stock Details
| Ticker Symbol | BMRA |
| Exchange | NASDAQ |
| Fiscal Year | June - May |
| Reporting Currency | USD |
| CIK Code | 0000073290 |
| CUSIP Number | 09061H307 |
| ISIN Number | US09061H3075 |
| Employer ID | 95-2645573 |
| SIC Code | 2835 |
Key Executives
| Name | Position |
|---|---|
| Zackary S. Irani | Chief Executive Officer |
| Allen C. Barbieri | Executive Vice-Chairman of the Board and Corporate Secretary |
| Gary Lu CPA | Principal Accounting Officer and Chief Financial Officer |
| Lucy Liu Ph.D. | Director of Manufacturing and Technical Operations |
| Robert W. Carlson | Chief Commercial Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Apr 12, 2024 | 10-Q | Quarterly Report |
| Feb 14, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Feb 9, 2024 | SC 13G | Statement of acquisition of beneficial ownership by individuals |
| Jan 16, 2024 | 10-Q | Quarterly Report |
| Dec 11, 2023 | 8-K | Current Report |
| Oct 12, 2023 | 10-Q | Quarterly Report |
| Sep 29, 2023 | EFFECT | Notice of Effectiveness |
| Sep 28, 2023 | S-3 | Registration statement under Securities Act of 1933 |
| Sep 27, 2023 | DEF 14A | Other definitive proxy statements |
| Sep 19, 2023 | 8-K | Current Report |